XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 28.10

+5.6%

Jan 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (10699)	7/9/1999 12:19:00 AM
From: aknahow	Read Replies (1) of 17367

Peter many of us agree that Neuprex is the main event. But the deal for Mycoprex is still an important item. Over 17 companies have signed cell expression agreements with XOMA and there are a dozen more talking deals. The hu1124 results might stimulate others to look at the XOMA huminization technology. In addition to fees XOMA gets royalties on any products that eventually hit the market for both humanization and cell expression technology use. Also Neuprex is a big subject. It might be just the P III unblinding which is considered the driver. There has always been lots of debate over the value of partnerships and so finally we have a company with a P III completed, and fairly good prospects of approval. Would think that's worth at lot more than a biotech that gave away 75% of the product to a partner. If you have not read the Endotoxin paper on the XOMA site it might be worth it. I am not 100% sure that the paper is an independent paper. The stock may not have done so great but their web site is several 100% above all the rest of the biotechs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next